Moderna and Merck Set New Benchmark in Personalized Melanoma mRNA Vaccine
The latest Phase 3 results against melanoma represent a landmark in cancer treatment history: for the first time, a personalized mRNA-based therapy has demonstrated, at scale, the ability to significantly reduce both recurrence and mortality of the deadliest form of skin cancer. Data released by the Moderna-Merck consortium in October 2026 show that combining the experimental vaccine intismeran autogene (mRNA-4157/V940) with Merck's immunotherapy Keytruda (pembrolizumab) reduced the risk of melanoma death or recurrence by 42% compared to standard treatment with Keytruda alone.
The INTerpath-001 trial enrolled more than 1,100 patients with stage IIB-IV melanoma whose tumors had been surgically removed. Among participants who received the personalized vaccine combined with Keytruda, 82.2% remained cancer-free after two years, versus 70% of patients who received immunotherapy alone. The risk of distant metastasis was reduced by 38%. These results build on the five-year data from the Phase 2b KEYNOTE-942 trial, published in June 2026 in the Journal of Clinical Oncology, which had already shown a 49% reduction in recurrence risk — but the Phase 3 study substantially enlarges the population and statistical power.
How the personalized vaccine works
Intismeran autogene is not a preventive vaccine in the traditional sense. Instead, it is an individualized neoantigen therapy: a sample of the patient's tumor is genetically sequenced to identify up to 34 unique mutations (neoantigens) that distinguish cancer cells from healthy ones. The synthetic mRNA is then engineered to instruct the immune system to recognize these specific markers. When administered after surgical tumor removal, the goal is to eliminate residual cells that could cause recurrence.
Meanwhile, Keytruda acts as a PD-1 blocker — a protein that tumors use to "turn off" immune responses. By blocking this escape pathway, the immunotherapy "releases the brakes" on T cells, enabling them to attack cancer more effectively. The combination of both approaches — a vaccine that teaches the immune system to recognize the enemy and an immunotherapy that removes the brakes — creates a synergistic effect without potentiating immune-related adverse events, according to trial data.
Dr. Hussein Tawbi, principal investigator of the trial and melanoma specialist at MD Anderson Cancer Center, described the results as "highly statistically significant." "It's not by chance," he emphasized, referring to the 42% reduction in the risk of death or recurrence, an effect that held across subgroup analyses.
From COVID-19 to cancer: the evolution of a platform
The mRNA-4157 journey toward Phase 3 results began in 2016, when Moderna and Merck established a strategic collaboration. In 2022, Merck exercised an option to jointly develop and commercialize the vaccine, sharing costs and profits equally. In February 2023, the combination received FDA breakthrough therapy designation.
The story is fascinating because it shows how a technology developed to combat a pandemic virus has proven capable of fighting one of the most resistant cancers. mRNA-4157 is the first investigational mRNA-based cancer treatment to demonstrate efficacy in a randomized oncology clinical trial — a milestone that opened the door to an entirely new class of therapies.
Today, the INTerpath program encompasses nine Phase 2 and Phase 3 clinical trials across melanoma, non-small cell lung cancer (NSCLC), bladder cancer, and renal cell carcinoma. Phase 1 studies are exploring applications in pancreatic, gastric, and perioperative NSCLC.
Market reaction with caution
Moderna shares surged more than 100% after the initial preliminary results were announced in August 2026, nearly quadrupling during the year. But when the full data were leaked on an oncology website and subsequently published on October 22, shares fell more than 17%, reflecting a typical "sell the news" behavior. William Blair analyst Myles Minter noted the data were "excellent," but investors would continue to debate the fundamental valuation of the intismeran franchise.
Merck shares fell only 1.8%, suggesting the market did not view the news as a surprise given the sequence of publications over the past three years.
RBC analysts, in a note following the results, expressed "less optimism" about pricing for the oncology franchise, arguing that melanoma was the "best case" — and even so, the 42% risk reduction falls short of the 50%+ recurrence cut expectations that some investors had priced in.
What to expect next
Moderna and Merck have already initiated regulatory conversations and expect to file for approval in the coming months. The launch is projected for 2027, according to CEO Stéphane Bancel. Before that, full data will be presented at the European Society for Medical Oncology (ESMO) meeting in Madrid, where researchers plan to reveal details on dosing, safety profiles, and response subgroups.
Bancel also suggested that intismeran, as a monotherapy in early-stage cancers, may have additional potential — information that, if confirmed, would significantly expand the vaccine's addressable market.
What distinguishes this therapy is not just the number, but the paradigm it represents: treatments designed from the unique genetic profile of each tumor. By 2027, if intismeran gains approval, it will not be alone for long — the INTerpath program continues to expand into new cancer types, and the experience accumulated with the mRNA platform is accelerating the next generation of neoantigen vaccines. The question is no longer whether personalized vaccines will transform oncology, but how rapidly they will replace standardized chemotherapy protocols — and whether public and private healthcare systems will be prepared to pay for a treatment that, by definition, is not a mass product but a therapy unique to each patient.
Sources: Ars Technica, Merck Corporate, Reuters / KELO-AM
✓ Independent sources cross-checked and verified before publishing
